skip to primary navigation skip to content

Alexandre Kabla
Mechanobiology and Soft Matter Group

Project

Glioblastoma heterogeneity

Glioblastoma recurs because cells at the margin escape surgery, yet the tumour core is often used to benchmark treatments. Combining fluorescence-guided sampling, a microfluidic adhesion assay and live-cell imaging on patient-derived cells, we showed that cells differ in adhesion and migration, and therefore in invasive potential (Rezk et al., Neuro-Oncology Advances 2020). Mechanobiological heterogeneity has to be measured and taken into account when treatments are validated. A 2025 follow-up shows that it also affects the response to metabolic and adhesion inhibitors (Rezk et al., Clinical and Experimental Medicine 2025). The project was led by Rasha Rezk when she was a post-doctoral research associate in Cambridge, and funded by the Nabaa El Mahaba charity (2018 to 2020).